In total, 135/500 (27%) women underwent germline testing, including every woman with established clinical (age ≤50 years, positive family history) or tumour characteristics (MMR deficient or MSI-H unexplained by MLH1-hypermethylation) predictive of LS; thus the prevalence of LS in the 365 (73%) women who did not undergo germline LS sequencing is expected to be extremely low. The gene discussed is MRC1; the disease is neoplasm.